Skip to main content

Zolgensma News

What You Should Know About Spinal Muscular Atrophy (SMA)

MONDAY, Aug. 11, 2025 — Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy A...

FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy

May 24, 2019 – The U.S. Food and Drug Administration today approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Spinal Muscular Atrophy

Zolgensma patient information at Drugs.com